Literature DB >> 25677027

Comparative effectiveness research in gynecologic oncology.

Sonali Patankar1, Ana I Tergas, Jason D Wright.   

Abstract

The field of gynecologic oncology is faced with a number of challenges including how to incorporate new drugs and procedures into practice, how to balance therapeutic efficacy and toxicity of treatment, how to individualize therapy to particular patients or groups of patients, and how to contain the rapidly rising costs associated with oncologic care. In this chapter we examine three common and highly debated clinical scenarios in gynecologic oncology: the initial management of ovarian cancer, the role of lymphadenectomy in the treatment of endometrial cancer, and the choice of adjuvant therapy for ovarian cancer.

Entities:  

Mesh：

Year:  2015        PMID： 25677027      PMCID： PMC4484275          DOI： 10.1007/978-3-319-12553-4_13

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


  86 in total

1.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

2.  Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?

Authors:  A Mariani; M J Webb; G L Keeney; M G Haddock; G Calori; K C Podratz
Journal:  Am J Obstet Gynecol       Date:  2000-06       Impact factor: 8.661

3.  Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.

Authors:  Jason D Wright; Cande V Ananth; Jennifer Tsui; Sherry A Glied; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  Cancer       Date:  2014-01-17       Impact factor: 6.860

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

5.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.

Authors:  C C Earle; J S Tsai; R D Gelber; M C Weinstein; P J Neumann; J C Weeks
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

7.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Authors:  M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

8.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

9.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Authors:  Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

Review 10.  The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review.

Authors:  Linda Dirven; Martin J B Taphoorn; Jaap C Reijneveld; Jane Blazeby; Marc Jacobs; Andrea Pusic; Edoardo La Sala; Roger Stupp; Peter Fayers; Fabio Efficace
Journal:  Eur J Cancer       Date:  2014-07-14       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.